Abstract: A compound represented by formula (I), and a racemate, a stereoisomer, a tautomer, an isotopic label, an N-oxide, a hydrate, a solvate, a polymorph, a metabolite, a pharmaceutically acceptable salt, a pharmaceutically acceptable ester, or a prodrug compound thereof are provided. This class of compounds has a good LRRK2 kinase regulation and inhibition and can be used for the treatment of an LRRK2 kinase activity-associated conditions and diseases, such as proliferative diseases, protein kinase-associated diseases, lysosomal diseases, Tau diseases, and diseases caused by decreased dopamine levels. etc.

Abstract: Antimicrobial agents, including antimicrobial peptides (AMPs), and uses thereof. Compositions and methods of using AMPs that demonstrate activity and improved therapeutic indices against microbial pathogens. The AMPs demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter-baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPs change selectivity from broad spectrum antimicrobial activity to Gram-negative selectivity.

Abstract: Antimicrobial agents, including antimicrobial peptides (AMPs), and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptide variants that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPs change selectivity from broad spectrum antimicrobial activity to Gram-negative selectivity.

Abstract: Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptide variants that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPs change selectivity from broad spectrum antimicrobial activity to Gram-negative selectivity.

Abstract: Antimicrobial agents, including antimicrobial peptides (AMPs), and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptide variants that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPs change selectivity from broad spectrum antimicrobial activity to Gram-negative selectivity.

Abstract: Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptide variants that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPs change selectivity from broad spectrum antimicrobial activity to Gram-negative selectivity.

Abstract: Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.

Abstract: Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens, The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.

Abstract: Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.

Abstract: A ballastless track system comprises a base; a track slab arranged above the base; a poured-field layer arranged between the base and the track slab, the poured-field layer being formed by filling self-compacting concrete, emulsified asphalt cement mortar or resin mortar, and the inside of the poured-field layer being of a steel bar structure; a connecting piece, the first end of the connecting piece extending into the track slab, and the second end of the connecting piece extending into the poured-field layer; and two rows of rail-seat arranged on the track slab in parallel; and rails arranged on the rail-seat. The ballastless track system is high in reliability, good in durability, and easy in construction and maintenance.

Abstract: Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.

Abstract: Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation.

Abstract: Provided in the disclosure is a pre-stressed concrete track slab of slab-type ballast-less track, which includes a slab body (1), on which fastening embedded casings (4) are arranged. At least one row of longitudinal common steel bars (11) and at least one row of transverse common steel bars (12) are arranged in the slab body (1) along a length direction and a width direction. The longitudinal common steel bars (11) are insulated from the transverse common steel bars (12). At least one row of longitudinal pre-stressed steel bars (7) and at least one row of transverse pre-stressed steel bars (6) are fastened in the slab body (1) along the length direction and the width direction through anchor backing plates and fastener devices (8). In the pre-stress directions of the longitudinal pre-stressed steel bars (7) and the transverse pre-stressed steel bars (6), it is post-tensioned in both directions or it is pre-tensioned in one direction and post-tensioned in the other direction.

Abstract: A ballastless track system comprises a base; a track slab arranged above the base; a poured-field layer arranged between the base and the track slab, the poured-field layer being formed by filling self-compacting concrete, emulsified asphalt cement mortar or resin mortar, and the inside of the poured-field layer being of a steel bar structure; a connecting piece, the first end of the connecting piece extending into the track slab, and the second end of the connecting piece extending into the poured-field layer; and two rows of rail-seat arranged on the track slab in parallel; and rails arranged on the rail-seat. The ballastless track system is high in reliability, good in durability, and easy in construction and maintenance.

Abstract: Provided in the disclosure is a pre-stressed concrete track slab of slab-type ballast-less track, which includes a slab body (1), on which fastening embedded casings (4) are arranged. At least one row of longitudinal common steel bars (11) and at least one row of transverse common steel bars (12) are arranged in the slab body (1) along a length direction and a width direction. The longitudinal common steel bars (11) are insulated from the transverse common steel bars (12). At least one row of longitudinal pre-stressed steel bars (7) and at least one row of transverse pre-stressed steel bars (6) are fastened in the slab body (1) along the length direction and the width direction through anchor backing plates and fastener devices (8). In the pre-stress directions of the longitudinal pre-stressed steel bars (7) and the transverse pre-stressed steel bars (6), it is post-tensioned in both directions or it is pre-tensioned in one direction and post-tensioned in the other direction.

Abstract: Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation.

Abstract: Disclosed herein are antimicrobial peptides with useful and/or superior properties such as specificity, resistance to degradation, antimicrobial activity, desirably low levels of hemolytic activity, and a therapeutic index against a broad range of microorganisms including gram-negative, gram-positive and acid-fast bacteria, fungi and other organisms. Also provided are pharmaceutical compositions comprising these peptides and methods of using such peptides to control microbial growth or to treat or reduce incidence of infections caused by such microorganisms. Also disclosed are peptides at least one or all amino acids in the D configuration. Compositions disclosed herein are useful in the treatment of bacterial, mycobacterial and/or fungal infections or for reducing microbial cell numbers or growth on surfaces or in materials.